Tumor necrosis factor receptor superfamily member 19 (TNFRSF19) (TNFRSF19)

Tumor necrosis factor receptor superfamily member 19 (TNFRSF19), commonly known as TROY, is a type I transmembrane receptor that serves as a critical regulator of microglial activation and recruitment within the central nervous system [1, 2]. While TROY is highly expressed during embryonic development, its expression in the adult brain is normally minimal but becomes significantly upregulated in microglia in response to pathological conditions such as glioblastoma [1, 6]. In the tumor microenvironment, TROY signaling facilitates microglial migration and infiltration through the activation of downstream pathways involving Pyk2, Rac1, and JNK, which contributes to tumor progression and invasion [1, 3, 18]. Beyond its role in oncology, TROY acts as a co-receptor in the Nogo receptor complex (NgR1/LINGO-1/TROY), where it mediates myelin-associated inhibition of neurite outgrowth and contributes to the failure of axonal regeneration following injury [4, 14, 18]. Therapeutic strategies targeting TROY, such as the use of the glial modulator propentofylline or JAK1 inhibitors like ruxolitinib, aim to disrupt these pro-invasive and anti-regenerative signaling pathways to improve outcomes in brain cancer and neurodegenerative diseases [1, 10, 11].

Other names

TROYTAJTRADEToxicity and JNK inducerTAJ-alphaTumor necrosis factor receptor superfamily member 19

Propentofylline acts as a glial modulator that decreases the expression of TROY and its downstream signaling effectors, including Pyk2, Rac1, and pJNK, in microglia, thereby inhibiting their migration and infiltration into tumor sites [1, 3]. Ruxolitinib inhibits Janus kinase 1 (JAK1), which is a key component of the TROY signaling complex (TROY-JAK1-STAT3) that promotes glioblastoma cell invasion and resistance to chemotherapy and radiation [10, 11].